Become a Member
News

Bilateral trade benefits from a taste of Israeli medicine

March 15, 2013 11:10
The Leviathan 4 oil platform off Israel’s Mediterranean coastline

By

Jennifer Lipman,

Jennifer Lipman

2 min read

Demand for Israeli medicines in the UK helped take bilateral trade between the two countries to a record high in the last calendar year.

Around £1.1 billion worth of Israeli-produced pharmaceuticals arrived in this country between January and December 2012, as British patients benefited from Israeli advancements, including drugs for Parkinson’s disease, such as Azilect, developed by Technion scientists, and from cheaper generic versions of drugs produced by Teva.

The boom in medical trade from Israel to the UK — up 11 per cent on 2011, and representing half of Israel’s exports to the UK — could be felt across Europe in the coming years, following a European Union vote in October which has finally ended a trade block on Israeli medicines.

In total, two-way trade reached more than £3.81 billion by the end of 2012, as compared with the £3.7 billion recorded for the previous year and on track for UK Trade and Investment’s target of topping £4 billion by the middle of the decade.